LH · 10-Q · 2026Q3 · Full report

End-Market Demand Trends

LABCORP HOLDINGS INC. · 2026-10-30 · Importance 43 · Surprise 32

For the three months ended September 30, 2026, Labcorp’s revenue increased 6.9% year over year, driven by 5.5% organic growth. Diagnostics (Dx) revenue grew 6.5%, with requisition volume up 4.8% and price/mix up 1.7%; organic Dx volume rose 3.1%. Bioanalytical and Laboratory Services (BLS) revenue grew 8.5%, driven by 9.6% organic growth, partly offset by divestiture-related strategic actions. For the nine-month period, Dx organic volume increased 2.0% and BLS organic growth was 6.6%, indicating growth across both segments.

Key facts

• Labcorp’s July 2025 OBBBA-related Medicaid and Affordable Care Act changes could reduce insurance coverage and diagnostics testing utilization, potentially decreasing revenue; Labcorp currently believes the reduction would not likely materially affect future-period operating results, and will evaluate impacts as provisions take effect through 2028. source